Alnylam Pharmaceuticals, Inc. (ALNY) Key Metrics
ALNY valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $31.02B
- Enterprise value
- $30.94B
- P/E (TTM)
- 39.1
- Forward P/E
- 19.7
- PEG ratio
- 0.32
- Price / sales
- 6.5 10-yr median 29.1
- Price / book
- 24.9 10-yr median 11.7
- EV / EBITDA
- 28.6
- Dividend yield
- —
- Beta
- 0.27
ALNY key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsALNY valuation Price multiples at each fiscal year-end price.
ALNY returns How much profit the business earns on the capital it uses.
ALNY per-share figures Results divided by the shares outstanding at year-end.
ALNY financial health Debt, liquidity and how easily interest is covered.
ALNY efficiency & capital use Working capital cycle and where the cash goes.
ALNY valuation history
ALNY returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ALNY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ALNY cash returned to shareholders
ALNY price vs earnings per share
ALNY key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $53.56B | $30.04B | $23.91B | $28.92B | $20.09B | $14.94B | $12.58B | $7.33B | $11.50B | $3.20B |
| Enterprise value | $51.93B | $28.64B | $22.77B | $28.05B | $18.65B | $13.59B | $11.35B | $6.34B | $9.84B | $2.42B |
| P/E ratio | 170.7 | — | — | — | — | — | — | — | — | — |
| Price / sales | 14.4 | 13.4 | 13.1 | 27.9 | 23.8 | 30.3 | 57.3 | 97.9 | 128.0 | 68.0 |
| Price / book | 67.9 | 447.7 | — | — | 34.1 | 14.7 | 8.7 | 5.6 | 6.5 | 3.5 |
| Price / free cash flow | 115.1 | — | 570.0 | — | — | — | — | — | — | — |
| Price / operating cash flow | 102.2 | — | 229.5 | — | — | — | — | — | — | — |
| EV / sales | 14.0 | 12.7 | 12.5 | 27.0 | 22.1 | 27.6 | 51.7 | 84.7 | 109.5 | 51.4 |
| EV / EBITDA | 82.2 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 111.6 | — | 543.0 | — | — | — | — | — | — | — |
| Earnings yield | 0.6% | −0.9% | −1.8% | −3.9% | −4.2% | −5.7% | −7.0% | −10.4% | −4.3% | −12.8% |
| Free cash flow yield | 0.9% | −0.1% | 0.2% | −2.1% | −3.6% | −4.6% | −3.3% | −9.4% | −4.2% | −11.6% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $397.65 | $235.31 | $191.41 | $237.65 | $169.58 | $129.97 | $115.17 | $72.91 | $127.05 | $37.44 |
| Per share | ||||||||||
| Revenue per share | $27.58 | $17.61 | $14.64 | $8.53 | $7.13 | $4.29 | $2.01 | $0.74 | $0.99 | $0.55 |
| Earnings per share | $2.33 | −$2.18 | −$3.52 | −$9.30 | −$7.20 | −$7.46 | −$8.11 | −$7.57 | −$5.42 | −$4.79 |
| Operating cash flow per share | $3.89 | −$0.07 | $0.83 | −$4.45 | −$5.42 | −$5.35 | −$2.55 | −$5.59 | −$4.23 | −$3.59 |
| Free cash flow per share | $3.46 | −$0.33 | $0.34 | −$5.04 | −$6.06 | −$5.96 | −$3.83 | −$6.85 | −$5.38 | −$4.35 |
| Cash per share | $21.59 | $21.11 | $19.53 | $18.02 | $20.56 | $16.30 | $14.06 | $10.77 | $18.82 | $11.01 |
| Book value per share | $5.86 | $0.53 | −$1.77 | −$1.30 | $4.97 | $8.84 | $13.17 | $12.94 | $19.51 | $10.75 |
| Tangible book value per share | $1.45 | $0.53 | −$7.35 | −$3.47 | $4.97 | $8.84 | $13.17 | $12.94 | $19.51 | $10.75 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.44 | $0.27 | $0.50 | $0.59 | $0.64 | $0.61 | $1.28 | $1.26 | $1.15 | $0.75 |
| Debt per share | $9.49 | $10.15 | $10.45 | $10.85 | $8.42 | $4.53 | $2.78 | $0.92 | $0.45 | $1.89 |
| Shares outstanding | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | 100.6M | 90.6M | 85.6M |
| Change in shares outstanding | +5.5% | +2.2% | +2.6% | +2.7% | +3.0% | +5.2% | +8.6% | +11.1% | +5.8% | +1.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 73.3% | — | — | — | −106.3% | −69.9% | −64.7% | −49.6% | −36.5% | −37.5% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −286.4% | −310.3% | −326.5% | −203.3% |
| Return on assets (ROA) | 6.8% | −6.9% | −11.9% | −31.5% | −24.2% | −29.6% | −44.6% | −42.7% | −30.1% | −31.0% |
| Return on tangible assets | 7.2% | −6.6% | −14.1% | −34.5% | −23.4% | −25.2% | −37.0% | −48.4% | −24.6% | −32.5% |
| Free cash flow margin | 12.5% | −1.9% | 2.3% | −59.1% | −85.0% | −139.1% | −190.5% | −920.5% | −541.6% | −789.4% |
| Income quality (OCF / net income) | 1.67 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.28B | $1.30B | $1.31B | $1.32B | $997.6M | $521.2M | $303.8M | $92.9M | $41.0M | $161.5M |
| Cash & short-term investments | $2.91B | $2.69B | $2.44B | $2.19B | $2.44B | $1.87B | $1.54B | $1.08B | $1.70B | $942.6M |
| Net debt | −$1.63B | −$1.40B | −$1.13B | −$872.2M | −$1.44B | −$1.35B | −$1.23B | −$990.1M | −$1.66B | −$781.1M |
| Debt / equity | 1.62 | 19.32 | — | — | 1.70 | 0.51 | 0.21 | 0.07 | 0.02 | 0.18 |
| Debt / assets | 0.26 | 0.31 | 0.34 | 0.37 | 0.27 | 0.15 | 0.13 | 0.06 | 0.02 | 0.13 |
| Net debt / EBITDA | −2.58 | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 4.98 | 8.99 | 5.14 |
| Quick ratio | 2.71 | 2.71 | 2.99 | 3.34 | 3.91 | 4.34 | 4.71 | 4.88 | 8.99 | 5.14 |
| Interest coverage | 2.0 | -1.2 | -2.3 | -5.0 | -5.0 | -9.8 | -8.7 | -27.8 | -40.9 | -51.1 |
| Working capital | $2.58B | $2.11B | $2.01B | $1.92B | $2.11B | $2.03B | $1.36B | $966.5M | $1.58B | $796.7M |
| Invested capital | −$840.9M | −$1.33B | −$1.35B | −$1.03B | −$849.8M | −$337.0M | $206.4M | $311.9M | $102.9M | $139.1M |
| Tangible asset value | $195.5M | $67.1M | −$918.4M | −$422.8M | $588.2M | $1.02B | $1.44B | $1.30B | $1.77B | $920.2M |
| Net current asset value | −$126.5M | −$877.6M | −$1.07B | −$1.01B | −$246.5M | $224.0M | $759.4M | $936.5M | $1.55B | $646.7M |
| Graham number | $17.52 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | −$4.78 | −$8.89 | −$10.57 | −$10.43 | −$3.61 | −$0.23 | $5.86 | $8.31 | $16.58 | $7.21 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $3.5M | $257,000 | $596,000 |
| Capex / revenue | 1.6% | 1.5% | 3.4% | 6.9% | 9.0% | 14.3% | 63.8% | 169.4% | 115.9% | 136.9% |
| Capex / operating cash flow | 11.2% | — | 59.7% | — | — | — | — | — | — | — |
| Capex / depreciation | 1.05 | 0.60 | 1.15 | 1.62 | 1.61 | 0.95 | 2.58 | 19.72 | 7.80 | 4.27 |
| Stock-based compensation / revenue | 9.4% | 12.1% | 12.1% | 22.2% | 19.6% | 28.4% | 79.6% | 210.6% | 103.2% | 160.2% |
| R&D / revenue | 35.7% | 50.1% | 54.9% | 85.1% | 93.8% | 132.9% | 298.1% | 674.7% | 434.5% | 810.9% |
| SG&A / revenue | 32.6% | 43.4% | 43.5% | 74.3% | 73.5% | 119.4% | 218.0% | 510.4% | 221.7% | 189.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 58.1 | 59.5 | 56.5 | 76.8 | 173.1 | 239.0 | 51.3 | 128.5 | 116.4 | 122.4 |
| Days of inventory on hand | 43.5 | 94.6 | 128.2 | 232.8 | 210.4 | 307.6 | 585.6 | 2,437.5 | 0.0 | 0.0 |
| Days payables outstanding | 55.0 | 81.2 | 90.3 | 185.4 | 163.3 | 238.1 | 798.0 | 8,918.7 | 26.1 | 28.1 |
| Cash conversion cycle (days) | 46.6 | 72.9 | 94.4 | 124.1 | 220.2 | 308.4 | -161.2 | -6,352.6 | 90.2 | 94.3 |
| Receivables turnover | 6.28 | 6.13 | 6.46 | 4.75 | 2.11 | 1.53 | 7.11 | 2.84 | 3.14 | 2.98 |
| Payables turnover | 6.63 | 4.49 | 4.04 | 1.97 | 2.24 | 1.53 | 0.46 | 0.04 | 13.96 | 12.97 |
| Inventory turnover | 8.40 | 3.86 | 2.85 | 1.57 | 1.73 | 1.19 | 0.62 | 0.15 | 578,100,000.00 | 462,146,000.00 |
| Asset turnover | 0.81 | 0.56 | 0.50 | 0.29 | 0.24 | 0.17 | 0.11 | 0.04 | 0.06 | 0.04 |
| Average receivables | $591.4M | $366.5M | $282.9M | $218.3M | $400.5M | $322.7M | $30.9M | $26.4M | $28.7M | $15.8M |
| Average payables | $102.1M | $72.0M | $76.8M | $85.8M | $62.7M | $50.9M | $54.8M | $44.0M | $41.4M | $35.6M |
| Average inventory | $80.6M | $83.8M | $109.1M | $107.7M | $80.8M | $65.8M | $40.2M | $12.0M | $1 | $1 |
| Intangibles / total assets | 12.0% | 0.0% | 18.2% | 7.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ALNY's annual financial statements (latest annual report filed February 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ALNY valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Alnylam traded at 170.7 times earnings. Based on the latest twelve months, the trailing P/E is 39.1 and the forward P/E is 19.7. Alnylam earned a return on equity of 73.3% in fiscal 2025. It ended the year with $1.3 billion of debt and $2.9 billion in cash and short-term investments, a net cash position of $1.6 billion. The share count rose 57.3% from 85.6M to 134.7M over 9 years.
See the ALNY income statement, the ALNY chart for price history, or the ALNY stock overview for the latest quote and news.
ALNY key metrics FAQ
What is Alnylam's P/E ratio?
Alnylam's trailing P/E ratio is 39.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 19.7. At the end of fiscal 2025 it was 170.7.
What is Alnylam's EV/EBITDA?
Alnylam's enterprise value was 82.2 times EBITDA at the end of fiscal 2025 (enterprise value $51.9 billion, EBITDA $631.4 million); the current EV/EBITDA is 28.6.
What is Alnylam's return on equity?
Alnylam's return on equity (ROE) was 73.3% in fiscal 2025: net income of $313.7 million on average shareholders' equity of $428.1 million.
How much debt does Alnylam have?
Alnylam had total debt of $1.3 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.62 and more cash than debt.
What is Alnylam's free cash flow yield?
Alnylam generated $465.4 million of free cash flow in fiscal 2025, a free cash flow yield of 0.9% on its market value at year-end ($53.6 billion).
What is Alnylam's current ratio?
Alnylam's current ratio was 2.76 at the end of fiscal 2025: current assets were 2.76 times current liabilities.